TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of glaucoma medications used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LH levels during AG infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: LH pulsatility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: LH response to naloxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: reduction in habitual responding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: child emotion regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dialysis dependency at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Freedom from target lesion revascularization (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total thiol protein (SH) group concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutathione peroxidase (GPx) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipoperoxidative markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ED
Endpoint domain: Adverse events/effects
Primary endpoint: Vasomotor symptoms scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intent to breastfeed for 6 months or longer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Support felt by respondents from their unit
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Support felt by respondents from the Army
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: extent of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of pain-related sleep interference
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: patient global impression of change scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ink penetration (in mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fasting serum triacylglycerol (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost-effectiveness of docetaxel
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Survival data for prostate cancer patients
Endpoint domain: Mortality/survival
Primary endpoint: experience of toothache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment and pregnancy outcomes for opioid‐dependent pregnant women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Grade > or = 4 pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease of anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes achieving 20/20 or better uncorrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes achieving 20/40 or better visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of refraction within 1.0 D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankle dorsiflexion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local progression-free survival (LPFS)
Endpoint domain: Mortality/survival
Primary endpoint: regional progression-free survival (RPFS)
Endpoint domain: Mortality/survival
Primary endpoint: MA use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time to normal lip sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal impairment incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total prolactin response to buspirone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Readmission for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite end-point events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak Vo2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean propofol infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Levels of satisfaction for endoscopists
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Root length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: MGL of the lower eyelid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GSRS-IBS symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic change in joint space width (JSW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic inflammatory responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial plasma glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postprandial plasma glucagon response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Active wrist extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frenchay Arm Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mixed venous oxygen saturation increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PANSS Negative subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death or bronchopulmonary dysplasia (day 28)
Endpoint domain: Mortality/survival
Primary endpoint: intraventricular hemorrhage >/=grade III
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of NH events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of NH events (measured by AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR-uncorrected ACPR at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PCR-corrected ACPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CFVR measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Control of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop out due to side effects
Endpoint domain: Adverse events/effects
Primary endpoint: suicidal ideation and behaviour
Endpoint domain: Adverse events/effects
Primary endpoint: cardiovascular problems
Endpoint domain: Adverse events/effects
Primary endpoint: Physical functioning subscore of the SF-36 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Distance score of the WIQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful task completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: plasma estrogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of visits with reported side effects
Endpoint domain: Adverse events/effects
Primary endpoint: MSHQ-EjD scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ADI engagement rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: family cohesion improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: serum levels of triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum activities of alanine aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: complete healing of the fissure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of anal incontinence
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in RMS HOAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in low mesopic contrast sensitivity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: real-world safety of sertindole treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of ovarian hyperstimulation syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraovarian androgen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Estradiol blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevention of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in sST2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal maturity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hs-CRP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TNF-α reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ADN increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to CBT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Insight into managing depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 24-h Energy Expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased acidic GER
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: DGER monitoring feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in hip structure analysis indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severity of gastric disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAV regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: global response assessment response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mask intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: range-of-motion recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: vertebral stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin-like growth factor-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of nonmalignant pericardial effusions
Endpoint domain: Adverse events/effects
Primary endpoint: Head extension angles for arytenoid exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head extension angles for best view of the glottis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of attacks of hereditary angioedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in adjusted HAM-D(17) total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in relative VO(2) max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACH-mediated forearm blood flow responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Differential expression of IL-32 isoforms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Induction of pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Induction of HIV-1 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: WOMAC scales (physical function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of discontinuation of PEP before day 28
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of adverse events reported
Endpoint domain: Adverse events/effects
Primary endpoint: Deep venous thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects becoming panic-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annualized number of injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: diabetic retinopathy severity scale improvement of ≥2 steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower extremity mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance performance (half-marathon time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity in nodule detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Specificity in nodule detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of SR‐NCWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incident SR‐NCWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severe hypertriglyceridaemia
Endpoint domain: Adverse events/effects
Primary endpoint: epidermal hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Relative risk reduction in cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stable weight achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Necrosis volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: paCO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: C4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Emotional role
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in nurses' perceptions of client autonomy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of perceived stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased sense of control
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral edema incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Average maximum diameter of the target volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering marijuana use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hard drug use effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage change from baseline in lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptation to the surrounding skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient satisfaction with the appearance of the skin graft
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hourly local anesthetic amount used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RH% increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of antithrombin III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma concentrations of protein C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain and discomfort associated with the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Preference of technique by trainees
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correction of renal anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Need for regular transfusion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Development or aggravation of hypertension
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of functional impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of CD4+CD25+ Tregs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mRNA level of FoxP3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of interferon‐γ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Obesity rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Creatinine clearance (CRCL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Feasibility and acceptability of DREAM-START intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improved attack frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in word-finding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in talking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptability of computerized aphasia therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lopinavir AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ritonavir AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to return to fetal heart rate reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of PEG-Intron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month abstinence rate
Endpoint domain: Mortality/survival
Primary endpoint: 12-month abstinence rate for smokers aged 45 and older
Endpoint domain: Mortality/survival
Primary endpoint: Total health-related costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bone turnover markers (C-terminal telopeptide and osteocalcin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contraceptive use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of chest compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transforming growth factor‐β1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interferon‐γ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overactive bladder symptom score total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: questionnaire short form scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall and late distant recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Skin temperature of hands and feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: percentage of CD3(+), CD4(+), CD8(+) T cell populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PCIS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual predicted medical care expenditures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Morphine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes